Voyager Therapeutics (VYGR)

• Market cap: $227M
• 1 day: 0.25%
• 5 days: -0.97%
• 1 month: 1.24%
• 3 months: -9.73%
• 6 months: 37.37%
• Year to date: -31.66%
• 1 year: -30.96%
• 5 years: -45.82%
• 10 years: -80.89%
• Sector: Healthcare
• Industry: Biotechnology

About: Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Employees: 172